Coagulopathy and Thromboembolism in Covid-19- A Review

Abstract

The emergence of the novel coronavirus, SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) has resulted in a major global pandemic posing various challenges to the worldwide health care systems. Clinical course of the infection, known as coronavirus disease of 2019 (COVID-19, ranges from mild subclinical disease to a life-threatening systemic illness. Common symptoms include a flu-like illness with fever and inflammation, and in severe cases pneumonia and systemic inflammation that results in morbidity and mortality. One of the complications of COVID-19 is its disruption of normal hemostasis resulting coagulopathy and thromboembolism. In this following review, we discuss present knowledge; summarize existing published information on the underlying mechanisms of action for COVID-19-associated coagulopathy; and propose algorithms for screening, management, and prevention of COVID-19 patients.